Sanofi-Aventis and Johns Hopkins join forces in asthma
This article was originally published in Scrip
Executive Summary
Sanofi-Aventisand the Johns Hopkins University School of Medicine are to jointly discover and develop new methods to treat respiratory diseases, in particular severe asthma and chronic obstructive pulmonary disease, as well as immuno-allergic diseases. Under a three-year agreement, the university's division of allergy and clinical immunology and the French company will work on new target identification, assay development and compound screening, and will collaborate on the design of potential clinical studies and the selection of biomarkers. Sanofi-Aventis already markets the allergy treatment Allegra (fexofenadine HCl) and has a number of NCEs at very early stages of development for asthma.
You may also be interested in...
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.